» Articles » PMID: 26493349

MMSA-1 Expression Pattern in Multiple Myeloma and Its Clinical Significance

Overview
Journal Clin Exp Med
Specialty General Medicine
Date 2015 Oct 24
PMID 26493349
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma-associated antigen-1 (MMSA-1) is a novel multiple myeloma (MM)-associated antigen which has been recently identified. Herein, we have tried to examine its clinical significance by studying the relationship between its expression and selected clinicopathological features. We extracted mononuclear cells from the bone marrow of MM patients and healthy donors and compared the MMSA-1 expression by RT-PCR and Western blot analysis. In addition, we also analyzed MMSA-1 expression in patients that were grouped based on selected clinical parameters. Moreover, the impact of MMSA-1 on patients' survival was also explored. MMSA-1 mRNA and protein were significantly upregulated in MM patients in comparison with healthy donors. Moreover, among the newly diagnosed and relapsed/refractory patients, the MMSA-1 expression was higher in relapsed/refractory patients. In addition, MMSA-1 mRNA expression not only showed significantly higher correlation with clinical parameters such as age, Durie and Salmon stage, bone lesion condition, albumin, creatinine and lactate dehydrogenase but also has a close relationship with myeloma bone disease-related cytokines, genetic abnormalities and treatment response. Multivariate COX analysis predicted MMSA-1 and LDH levels to be independently associated with a poor progression-free survival and overall survival in myeloma patients. Our findings provide initial proof of concept that MMSA-1 is a potent gene that is specifically expressed in MM patients and could be a feasible biomarker and independent prognostic factor.

Citing Articles

Involvement of ZDHHC9 in lung adenocarcinoma: regulation of PD-L1 stability via palmitoylation.

Li Z, Jiang D, Liu F, Li Y In Vitro Cell Dev Biol Anim. 2023; 59(3):193-203.

PMID: 37002491 DOI: 10.1007/s11626-023-00755-5.


Protein palmitoylation and cancer.

Ko P, Dixon S EMBO Rep. 2018; 19(10).

PMID: 30232163 PMC: 6172454. DOI: 10.15252/embr.201846666.


Current treatment options of T cell-associated immunotherapy in multiple myeloma.

Liu H, Pan Y, Meng S, Zhang W, Zhou F Clin Exp Med. 2017; 17(4):431-439.

PMID: 28120217 DOI: 10.1007/s10238-017-0450-9.

References
1.
van de Donk N, Sonneveld P . Diagnosis and risk stratification in multiple myeloma. Hematol Oncol Clin North Am. 2014; 28(5):791-813. DOI: 10.1016/j.hoc.2014.06.007. View

2.
Shibayama H . [Supportive care in multiple myeloma for continuing anti-myeloma therapies]. Rinsho Ketsueki. 2014; 55(10):1999-2004. View

3.
Basit A, Siddiqui N, Hameed A, Muzaffar N, Athar S . Factors affecting outcome of patients with multiple myeloma. J Ayub Med Coll Abbottabad. 2015; 26(3):376-9. View

4.
Hosen N . [Multiple myeloma stem cell]. Nihon Rinsho. 2015; 73(1):47-51. View

5.
Zhou F, Zhang W, Chen G, Zhao W, Cao X, Chen Y . Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma. Cancer Immunol Immunother. 2005; 55(8):910-7. PMC: 11030602. DOI: 10.1007/s00262-005-0074-x. View